These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 8339288

  • 1. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
    Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR.
    Cancer Res; 1993 Aug 15; 53(16):3758-64. PubMed ID: 8339288
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
    Kaijser GP, Keizer HJ, Beijnen JH, Bult A, Underberg WJ.
    Anticancer Res; 1996 Aug 15; 16(5B):3247-57. PubMed ID: 8920799
    [Abstract] [Full Text] [Related]

  • 3. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
    Kerbusch T, Mathôt RA, Keizer HJ, Kaijser GP, Schellens JH, Beijnen JH.
    Drug Metab Dispos; 2001 Jul 15; 29(7):967-75. PubMed ID: 11408362
    [Abstract] [Full Text] [Related]

  • 4. Comparison of continuous infusion and bolus administration of ifosfamide in children.
    Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD, Idle JR.
    Eur J Cancer; 1995 Jul 15; 31A(5):785-90. PubMed ID: 7640054
    [Abstract] [Full Text] [Related]

  • 5. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
    Boddy AV, Cole M, Pearson AD, Idle JR.
    Cancer Chemother Pharmacol; 1995 Jul 15; 36(1):53-60. PubMed ID: 7720176
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of ifosfamide and some metabolites in children.
    Kaijser GP, De Kraker J, Bult A, Underberg WJ, Beijnen JH.
    Anticancer Res; 1998 Jul 15; 18(3B):1941-9. PubMed ID: 9677448
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
    Passe P, Delepine N, Arnaud P, Urien S, Delepine G, Traoré F, Desbois JC, Brion F.
    Anticancer Res; 1999 Jul 15; 19(1B):837-42. PubMed ID: 10216502
    [Abstract] [Full Text] [Related]

  • 8. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
    Boddy AV, English M, Pearson AD, Idle JR, Skinner R.
    Eur J Cancer; 1996 Jun 15; 32A(7):1179-84. PubMed ID: 8758250
    [Abstract] [Full Text] [Related]

  • 9. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
    Silies H, Blaschke G, Hohenlöchter B, Rossi R, Jürgens H, Boos J.
    Int J Clin Pharmacol Ther; 1998 May 15; 36(5):246-52. PubMed ID: 9629987
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
    Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR.
    Eur J Cancer; 1995 May 15; 31A(1):69-76. PubMed ID: 7695982
    [Abstract] [Full Text] [Related]

  • 11. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
    Baranzelli MC, Pichon F, Gourmel B, N'Guyen M, Deligny N, Demaille MC.
    Bull Cancer; 1997 Feb 15; 84(2):141-6. PubMed ID: 9180836
    [Abstract] [Full Text] [Related]

  • 12. Studies on the human pharmacokinetics of isophosphamide (NSC-109724).
    Allen LM, Creaven PJ, Nelson RL.
    Cancer Treat Rep; 1976 Apr 15; 60(4):451-8. PubMed ID: 1277221
    [Abstract] [Full Text] [Related]

  • 13. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
    Boos J, Welslau U, Ritter J, Blaschke G, Schellong G.
    Klin Padiatr; 1992 Apr 15; 204(4):299-305. PubMed ID: 1518269
    [Abstract] [Full Text] [Related]

  • 14. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
    Cerny T, Leyvraz S, von Briel T, Küpfer A, Schaad R, Schmitz SF, Honegger P, Sessa C, Brunner J, Boddy AV.
    Ann Oncol; 1999 Sep 15; 10(9):1087-94. PubMed ID: 10572607
    [Abstract] [Full Text] [Related]

  • 15. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    J Clin Oncol; 2007 Jul 20; 25(21):3144-50. PubMed ID: 17634494
    [Abstract] [Full Text] [Related]

  • 16. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
    Yule SM, Price L, Pearson AD, Boddy AV.
    Clin Cancer Res; 1997 Nov 20; 3(11):1985-92. PubMed ID: 9815588
    [Abstract] [Full Text] [Related]

  • 17. Ifosfamide metabolism and pharmacokinetics (review).
    Kaijser GP, Beijnen JH, Bult A, Underberg WJ.
    Anticancer Res; 1994 Nov 20; 14(2A):517-31. PubMed ID: 8017856
    [Abstract] [Full Text] [Related]

  • 18. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E, Cloyd J, Critchley D, Fuseau E.
    Epilepsia; 2008 Jul 20; 49(7):1123-41. PubMed ID: 18503564
    [Abstract] [Full Text] [Related]

  • 19. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
    Brain EG, Rezai K, Weill S, Gauzan MF, Santoni J, Besse B, Goupil A, Turpin F, Urien S, Lokiec F.
    Cancer Chemother Pharmacol; 2007 Aug 20; 60(3):375-81. PubMed ID: 17106751
    [Abstract] [Full Text] [Related]

  • 20. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA.
    Toxic Rep Ser; 1999 Aug 20; (59):1-66, A1-E7. PubMed ID: 11803702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.